

# Yong Liang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11952007/publications.pdf>

Version: 2024-02-01

19  
papers

1,523  
citations

623734

14  
h-index

752698

20  
g-index

20  
all docs

20  
docs citations

20  
times ranked

3182  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 580-588.	8.2	388
2	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. <i>Nature Communications</i> , 2020, 11, 4835.	12.8	290
3	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
4	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. <i>Nature Communications</i> , 2019, 10, 3874.	12.8	132
5	Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota. <i>Immunity</i> , 2015, 42, 731-743.	14.3	102
6	Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. <i>Science Translational Medicine</i> , 2016, 8, 333ra47.	12.4	83
7	A Dendritic-Cell-Stromal Axis Maintains Immune Responses in Lymph Nodes. <i>Immunity</i> , 2015, 42, 719-730.	14.3	69
8	Targeting IFN $\gamma$ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2018, 9, 4586.	12.8	60
9	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. <i>Nature Communications</i> , 2021, 12, 5866.	12.8	39
10	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	38
11	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	7.0	35
12	Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. <i>Cell Research</i> , 2021, 31, 1190-1198.	12.0	34
13	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1 <sup>int</sup> Tim-3 <sup>hi</sup> CD8 <sup>+</sup> T cells. <i>JCI Insight</i> , 2020, 5, .	5.0	30
14	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 3818-3824.	7.0	21
15	STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 60.	1.7	13
16	Deficiency of CD40 Reveals an Important Role for LIGHT in Anti-Leishmanial Immunity. <i>Journal of Immunology</i> , 2015, 195, 194-202.	0.8	11
17	Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication. <i>Scientific Reports</i> , 2015, 5, 10406.	3.3	8
18	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. <i>Scientific Reports</i> , 2018, 8, 17727.	3.3	7

#	ARTICLE	IF	CITATIONS
19	T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response. Journal of Virology, 2018, 92, .	3.4	7